Power3 Medical Initiates Study of Nuropro® Diagnostic Test

Study Is Last Step Before Commercialization Of NuroPro Early Detection Test

THE WOODLANDS, Texas -- Power3 Medical Products, Inc. (OTCBB: PWRM), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, commenced a 300 patient clinical validation study of its NuroPro diagnostic test for Alzheimer’s disease and Parkinson’s disease.

The clinical validation study will be a blinded study of Power3’s NuroPro diagnostic test, which is a blood test for the detection of Alzheimer’s and Parkinson’s disease, with Dr. Marwan Sabbagh as the Principle Investigator at the Cleo Roberts Center of Clinical Research at the Sun Health Research Institute (SHRI). The study includes one hundred Alzheimer’s disease patients, one hundred Parkinson’s disease patients and one hundred controls. The Parkinson’s disease patients in the clinical validation study will augment the Parkinson’s disease validation study presently ongoing with the Research Institute of Thessaly in Greece led by Katerina Markopoulou, the Principal Investigator.

“The medical community continues its quest for a reliable blood test to be used as a diagnostic for Alzheimer’s disease,” said Dr. Sabbagh. “The Power3 test could provide the answer with its identification of protein biomarkers for Alzheimer’s and the development of a blood serum diagnostic. We, at SHRI, are excited to contribute to this important project.”

The NuroPro is based on Power3’s discovery of a group of fifty-nine proteins in the blood that demonstrate significant differences in blood serum concentration for patients with Alzheimer’s and Parkinson’s disease. In blood serum, these protein biomarker combinations, when measured by blood serum proteomics, will lead to a more effective diagnosis and treatment of Alzheimer’s and Parkinson’s disease.

Power3 expects expect to launch the NuroPro test for Alzheimer’s disease and Parkinson’s disease at the conclusion of this clinical validation study, which is expected to be late in calendar year 2008.

“We look forward to the conclusion of these studies and to moving forward with the commercialization of our blood serum diagnostic tests for the early detection of Alzheimer’s and Parkinson’s disease,” commented Steve Rash, Chief Executive Officer of Power3. “The company launched our BCSeraPro, an early detection diagnostic test for breast cancer, in the Middle East in October through a distribution agreement. We are proud that our research, discovery of protein biomarkers, and development of BCSera-Pro and NuroPro early detection tests are so close to commercialization in the U.S. We are on the brink of offering these blood serum-based tests that will meet a tremendous need for early detection methods for breast cancer and neurodegenerative diseases.”

About Power3 Medical Products
Power3 Medical Products, Inc. (OTCBB: PWRM), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro™, in twelve Middle Eastern countries before the end of 2007. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas. The Company is preparing to commercialize its IP portfolio, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s, and Parkinson’s Diseases.